Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and... see more

TSXV:RHT.H - Post Discussion

Reliq Health Technologies Inc > Also about gross margin...
View:
Post by theinvestor22 on Mar 04, 2023 6:59pm

Also about gross margin...

There have been lots of comments about gross margin over the years.  Just for the record, from my notes, here are the gross margin percentages since the reset:
 
f2019 (whole year)     4.3%
f2020 (whole year)   15.3%
f2021 (whole year)   58.7%
f2022 (whole year)   62.0%
f2023 (year-to-date) 62.4%
 
Not bad, and improving.
Comment by lscfa on Mar 04, 2023 7:55pm
All of these improving fundamentals are disappointing when compared to almost $1 billion/yr in contracts announced. Reliq mgmt, get on with it.  We're all dead in the long run. 
Comment by RottenRonnie7 on Mar 05, 2023 9:28pm
Hey buckaroos, your ol friend ranger RR here. Some nice thoughts on the weekend from the faithful here, sad really, i hate spewin this same shite but, HELLO, i keep reading the same misguided drool about how blue the skies are goin to be once we make it to Babylon with our saviour Lisa Crossley.  This was the my thought in the 2nd season of this ridiculous reality show, which, incidentally ...more  
Comment by EdinColorado on Mar 06, 2023 12:53pm
  With all the hard work they put into getting contracts in recent years this should kick in as income from onboarding patients in 2023 and undisputable revenue. I surely hope so. If we are still stuck in the ditch at SP of .51 later this year, we will have run out of rationalizations and excuses for failure to thrive.   
Comment by qwerty22 on Mar 06, 2023 2:35pm
We'll have to see what "nagging" (her word) patients into adherence will do to this. Sounds negative! Is that plateauing?  
Comment by Lifeboat1 on Mar 06, 2023 2:47pm
The Company has already been doing the adherence on new accounts and have improved it to >70%.  If they can continue that with all accounts we will see over a 3x increase in revenue in 2023 without adding any additional patients.
Comment by theinvestor22 on Mar 06, 2023 3:01pm
qwerty, I think you're asking whether or not the GM% is leveling off?  If that's your question, then I have two thoughts on that.  Fistly, a 62.4% GM is really good for revenue that's a blend of SaaS and devices.  And, it should naturally go up as SaaS revenue as a percentage of total revenue increases.  So, I'd be happy with that.  Secondly, the company ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities